Brokerages Set Evolent Health, Inc. (NYSE:EVH) PT at $43.00

Evolent Health, Inc. (NYSE:EVH) has earned a consensus rating of “Moderate Buy” from the twelve ratings firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $42.70.

Several equities analysts recently commented on EVH shares. Barclays started coverage on shares of Evolent Health in a research note on Wednesday, January 3rd. They set an “overweight” rating and a $39.00 price objective for the company. JPMorgan Chase & Co. reduced their price objective on shares of Evolent Health from $53.00 to $52.00 and set an “overweight” rating for the company in a research note on Friday, March 15th. JMP Securities boosted their price objective on shares of Evolent Health from $37.00 to $38.00 and gave the company a “market outperform” rating in a research note on Friday, February 23rd. Oppenheimer assumed coverage on shares of Evolent Health in a research note on Friday, March 1st. They set an “outperform” rating and a $45.00 price objective for the company. Finally, Canaccord Genuity Group cut their price target on shares of Evolent Health from $45.00 to $44.00 and set a “buy” rating for the company in a research note on Thursday, March 28th.

Evolent Health Price Performance

EVH opened at $29.86 on Friday. The company has a market capitalization of $3.45 billion, a price-to-earnings ratio of -23.51 and a beta of 1.54. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 0.56. The firm has a 50-day moving average price of $31.93 and a 200-day moving average price of $30.26. Evolent Health has a twelve month low of $23.33 and a twelve month high of $36.70.

Evolent Health (NYSE:EVH) last issued its quarterly earnings data on Thursday, February 22nd. The technology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.02 by $0.13. The company had revenue of $556.06 million during the quarter, compared to analysts’ expectations of $541.87 million. Evolent Health had a negative net margin of 5.76% and a positive return on equity of 6.60%. Equities analysts expect that Evolent Health will post 0.87 EPS for the current year.

Institutional Investors Weigh In On Evolent Health

Hedge funds have recently made changes to their positions in the business. ICA Group Wealth Management LLC bought a new stake in shares of Evolent Health in the 4th quarter worth approximately $33,000. Signaturefd LLC lifted its holdings in shares of Evolent Health by 1,470.7% in the 4th quarter. Signaturefd LLC now owns 1,445 shares of the technology company’s stock worth $48,000 after acquiring an additional 1,353 shares during the last quarter. NBC Securities Inc. bought a new stake in shares of Evolent Health in the 4th quarter worth approximately $69,000. Banque Cantonale Vaudoise bought a new stake in shares of Evolent Health in the 1st quarter worth approximately $88,000. Finally, Nisa Investment Advisors LLC lifted its holdings in shares of Evolent Health by 389.3% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,035 shares of the technology company’s stock worth $137,000 after acquiring an additional 4,006 shares during the last quarter.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.